Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-08-30 00:00:00 ET · period of report 2024-08-28 · accession 0002001011-24-000080 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-08-30 | 2024-08-28 | LGND | Espinoza Octavio | CFO | M - OptEx | $66.52 | +753 | 23.9K | +3% | +$50.1K |
| DM | 2024-08-30 | 2024-08-28 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -753 | 7,309 | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-28 | M | A | 546 | $70.04 | 24,399 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-28 | M | A | 207 | $57.22 | 23,853 | D | — | — | |
| 3 | Derivative | Incentive Stock Option (right to buy) | 2024-08-28 | M | D | 546 | $0.00 | 0 | D | $70.04 · — to 2029-02-01 | 546 Common Stock | (F2) As per the separation of OmniAb Inc. from the issuer, 402 stock options were vested and exercisable as of November 1, 2022, whereas 144 options vest in 3 substantially equal monthly installments beginning on December 1, 2022. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2024-08-28 | M | D | 207 | $0.00 | 7,309 | D | $57.22 · — to 2030-10-01 | 207 Common Stock | (F1) The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter. |